Pomalidomide: Thalidomide analogue for multiple myeloma

Abstract

Pomalidomide (Pomalyst—Celgene), an analogue of thalidomide, has received FDA approval for patients with multiple myeloma who have received at least two prior therapies including lenalidomide (Revlimid— Celgene) and bortezomib (Velcade—Millennium) and have demonstrated disease progression on or within 60 days of completion of the last therapy. The drug was approved under FDA’s accelerated approval program.